Member Info for peterobert

Under the Agreement, Engsolve, now a wholly owned subsidiary of Powerhouse

Energy Group, will undertake the Front-End Engineering Design (FEED) for the

facilities, which would be fully funded by National H2, ensuring a seamless

and well-supported development process.

In addition, Powerhouse and National H2 would work closely with the chosen

Engineering, Procurement, and Construction (EPC) contractor. This collective

effort will harness the expertise of all parties involved, enabling the

successful realization of these projects, each of which would be subject to

further project specific documentation being entered into at the time between

PHE and National H2.

Up today

9.51-9.875p

Good time to BUY before next news

imho - dyor

8.43p up 36%

Ondine Biomedical Inc on Wednesday said that the research it presented at a conference in San Francisco proves the efficacy of its Steriwave nasal photo disinfection system.

According to the Vancouver-based life sciences company, the system significantly reduces pathogens in the nose but does not produce long-term adverse effects on the nasal microbiome.

The research, which was presented at the SPIE Photonics West conference in San Francisco, demonstrated an immediate and highly significant reduction in viable bacterial cells and number of species, sustained for at least 24 hours.

"These findings support Steriwave as an efficient, potent, short-acting, and non-selective method of nasal decolonization, with the advantage of rapid recovery of the native microbiome post-treatment," Ondine commented.

Ondine Biomedical shares were trading 1.3% lower at 10.11 pence each in London on Wednesday afternoon.

By Holly Beveridge, Alliance News reporter

Research presented by Canadian life sciences company, Ondine Biomedical Inc. (LON:OBI), at the prestigious SPIE Photonics West conference in San Francisco, California shows that treatment with its Steriwave® Nasal Photodisinfection System significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome.[*]

Upon analysis of nasal swab samples, the research demonstrated an immediate and highly significant (99.9+% ~3 log10) reduction in viable bacterial cells and number of species, sustained for at least 24 hours. Importantly, within a week, the microbiome rebounded to its original diversity and quantity. These findings support Steriwave as an efficient, potent, short-acting, and non-selective method of nasal decolonization, with the advantage of rapid recovery of the native microbiome post-treatment.

In comparison to antibiotics, the study demonstrated that Steriwave is far less likely to significantly alter the native microbiota. The antibiotic mupirocin, commonly used for nasal decolonization, has been shown to affect microbiota diversity for over 6 months, allowing disease-causing pathogens like Staphylococcus aureus to colonize the nose before beneficial species, putting patients at increased risk of infection.[1] Steriwave, in contrast, offers a more favourable profile with the study results showing a reduced risk of long-term microbiome disruption, as the microbiome consistently returns to baseline.

Notably, minimizing microbiome disruption is also important in safeguarding immune function, reducing vulnerability to infectious diseases by maintenance of a microecological environment populated by beneficial commensal microbes instead of disease-causing species.[2] The oral research presentation, delivered by Ondine's Director of Research and Development, Dr. Caetano Sabino, reported results from an exploratory study involving 35 healthy volunteers, examining the responses of the nasal microbial population after Steriwave treatment.

Ondine Biomedical Inc. is a Canadian life science company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave®. It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present new research at the SPIE Photonics West conference in San Francisco, California. The presentation will provide details of an exploratory study showing that photodisinfection significantly reduces pathogens in the nose - a reservoir for bacteria - yet does not produce long-term adverse effects on the nasal microbiome.1 Organised by SPIE, the international society for optics and photonics, SPIE Photonics West is the largest annual event for optic and photonic technologies and one of the largest scientific conferences in the world.

These results demonstrate that Steriwave is an effective, potent, short-acting, and non-selective method of nasal decolonization, while permitting rapid recovery of the native microbiome at one week after treatment. The study involved analyzing nasal swabs from 35 healthy volunteers after being treated with Ondine's Steriwave® Nasal Photodisinfection System.

The oral presentation will be delivered by Ondine's Director of Research and Development, Dr Caetano Sabino, at 9am on Tuesday, 30 January 2024, as part of the "Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases" session.

The "Microbiome Analysis of Photodynamic Nasal Decolonization" abstract can be accessed here.

Just topped up

Expect good times this year

Yes -totally agree

RBC target 60p

Expect that to be a minimum

imho dyor

Possitive cash flow so no need for more fundraising

imho - dyor

10.188-10.84

Looking at he possibilities in USA will be the big one though

Soon

9.695-9.88p

Https://www.marketscreener.com/insider/JOSEPH-ERRICO-A1M2IX/

And this is just the beginning

RBC capital target 60p

9.575-9.999p

Jonboi1968 speaks the truth

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) has appointed Joseph P. ("JP") Errico as Chief Financial Officer.[i] JP will be responsible for managing and developing Ondine's finance function, as well as managing the capital markets interface, participating in discussions with large health systems and customers, and working closely with the management team on overall growth strategy, both from a financial and operational perspective.

JP has successfully founded and sold (or taken public) several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore, with his patented products generating over $20 billion in sales.

Carolyn Cross, CEO and founder of Ondine commented:

"We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare."

JP Errico commented:

"Ondine represents a unique opportunity to create shareholder value while heading off one of humanity's greatest health threats, antimicrobial resistance. I am proud to be joining an excellent team of professionals as Ondine brings this critically needed technology to the world."

JP's educational background includes an undergraduate degree in Aeronautical Engineering from the Massachusetts Institute of Technology and graduate degrees in both Law and Mechanical/Materials Engineering from Duke University. He is also a trained patent attorney.